The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients.<br> <span style="color: #009B77;">by Linda Stein Gold, MD</span> Oct 21 The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients. by Linda Stein Gold, MD 12:15 pm - 1:15 pm
The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation<br> <span style="color: #009B77;">by Fred Ghali, MD</span> Oct 21 The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation by Fred Ghali, MD 12:15 pm - 1:15 pm
DUPIXENT<sup>@</sup> (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Zakiya Rice, MD</span> Oct 22 DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Zakiya Rice, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age <br> <span style="color: #009B77;">by Marshall Shuler, MD</span> Oct 23 Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Marshall Shuler, MD 12:15 pm - 1:15 pm
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Ben Ehst, MD</span> Oct 29 Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ben Ehst, MD 12:15 pm - 1:15 pm
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Marc Serota, MD</span> Oct 30 A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Marc Serota, MD 12:15 pm - 1:15 pm
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Karan Lal, DO</span> Nov 3 A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Karan Lal, DO 12:15 pm - 12:45 pm
DUPIXENT<sup>@</sup> (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Omar Noor, MD</span> Nov 3 DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Omar Noor, MD 12:15 pm - 1:15 pm
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)<br> <span style="color: #009B77;">by Daniel Butler, MD</span> Nov 6 Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Daniel Butler, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age <br> <span style="color: #009B77;">by Brittany Craiglow, MD</span> Nov 12 Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Brittany Craiglow, MD 12:15 pm - 1:15 pm
